https://www.selleckchem.com/pr....oducts/evobrutinib.h
Data were statistically analysed using SPSS version 25 via the Dunn test and Kruskal-Wallis test. No bone remodeling was noted in any group at 1 month. The risedronate group showed significantly higher bone fill than the other groups after 2 months ( = 0.016). At 2 months, the number of osteoblasts was significantly higher in the risedronate group ( 0.05). The groups were not significantly different in terms of inflammation score at 1 ( = 0.31) or 2 ( =0.69) months. Foreign body reaction was not observed in any group at any tim
Me gusta
Comentario
Compartir
